Kayla T. O’Toole

This study identifies RAS(ON) inhibitors effective against NRAS-mutated melanoma and reveals resistance mechanisms through Ppia and Map2k1 mutations.

The paper identifies a novel interaction between BRAFV600E and TP53 in melanoma, suggesting that BRAFV600E inactivates TP53, explaining the rarity of TP53 alterations in this cancer type.

This study identifies HNF4 as a driver of hybrid-identity states in KRAS-driven lung adenocarcinoma, showing that opposing lineage specifiers promote tumor progression and affect therapy response.

This study shows that combining ULK1/2 inhibition with KRASG12C inhibitors reduces lung cancer growth in preclinical models.